CEO Today Global Awards

Delivering on promises is what we do at CSL. Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world. CSL’s strong commitment to living our Values has guided us for many decades. Our Values have been fundamental to our success — helping us to save lives, protect the health of people, and earn our reputation as a trusted and reliable global leader. They’re at the core of how our employees interact with each other, make decisions and solve problems. We focus on rare and serious diseases and influenza vaccines. Today, we compete on the global stage as one of the largest and fastest-growing protein-based biotechnology businesses and a leading provider of in-licensed vaccines. The Commonwealth Serum Laboratories was established in Australia in 1916 to service the health needs of a nation isolated by war. Over the ensuing years CSL provided Australians with rapid access to 20th century medical advances including insulin and penicillin, and vaccines against influenza, polio and other infectious diseases. CSL Limited was incorporated in 1991 and listed on the Australian Securities Exchange (ASX) in 1994. Since then, CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotech leader CSL Behring, U.S. plasma collector Nabi, which helped to form the world’s premier plasma collection company in CSL Plasma, the Novartis influenza vaccine business, now integrated and known as Seqirus, the world’s second largest influenza vaccines company and Calimmune, a leader in gene-modification and cell delivery technology. Their combined and rich histories make CSL the innovative global leader it is today. At CSL, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities. We believe that behaving responsibly is critical to the sustainability of our company. We align Corporate Responsibility with our business goals and ensure that it complements our unique capabilities and benefits our diverse set of stakeholders. About Paul Perreault Director of CSL Limited since February 2013, and appointed Chief Executive Officer and Managing Director in July 2013. Mr Perreault has more than 35 years of experience across both the global biotech and pharmaceutical industries. He was appointed Chief Executive Officer and Managing Director of CSL Limited in July 2013, and was appointed to the CSL Board of Directors the same year. Since then, CSL has grown to become the fifth largest biotech company in the world with more than 25,000 employees bringing lifesaving medicines to people in more than 70 countries. Mr Perreault, who previously served as CSL Behring’s President, joined CSL in 2004 with the acquisition of Aventis Behring. Prior to CSL, he spent more than 15 years in key senior roles at Wyeth-Ayerst Laboratories, now part of Pfizer. Mr Perreault holds a bachelor degree in psychology from the University of Central Florida and completed advanced business management training at the Kellogg and Wharton schools of business. CEO Today Global Awards 2020 AUSTRALIA 101 www.ceotodaymagazine.com